Cell-Free DNA (cf-DNA) Testing Market 2019-2025
This study focuses on the volume and quality testing at international, national, and company level for Cell-Free DNA (cf-DNA). This study from the global point of view reflects aggregate tests on the market size of cell free DNA (cf. DNA) by review of historical data and future prospects. The new technology for free-flowing DNA fragmentation was cell-free DNA testing and analyzed from a small amount of fluid samples from patients (saliva, urine, or blood). The Cell-free DNA (cfDNA) testing market is primarily driven by the following factors:
Cell-free DNA is a fragment of DNA that circulates through the blood stream and is useful as a biomarker. The new technology is used for analyzing the freely circulating DNA in small quantities of liquid sample (saliva, urine or blood). Cell-Free DNA (cfDNA) is a noninvasive screening test used to detect rejection of graft, to recognize mutations in patients with cancer, and to detect various fetal chromosomal abnormalities, to know the fetus ‘ sex. In the field of oncology, gynecology, transplantation and infectious diseases the discovery of cfDNA has opened up new opportunities.
The major manufacturers covered in this report
Agilent Technology, Allenex, Biocept, Biodesix, CareDx, Guardant Health, Illumania, Invited, Natera, Quest Diagnostics, Roche, Sequenom, Trovagene, ………….
Usage forms and area separates the cell-free DNA test segment. The market is divided into oncology, gynecology and transplantation according to usage. The market is also categorized into cell free DNA (ddcfDNA) from donors, circulating cell-free tumor DNA (ktDNA) and non-cell fetal DNA (NIPT). By type the market is divided into the cell-free DNA test, based on donor tests, investigates the rejection of the grease in trans-plantated patients by recognizing the absence or existence of donor DNA in the blood. In the urine, saliva and/or blood of the cancer patients to identify mutation, ctDNA screening tests circulating tumor DNA.
The geographical categorisation of CDN (cf-DNA) Tests in North America, Europe, China, Japan, South-East Asia and India involves development, apparent use, export and import of CDNA (cf-DNA). This report analyzes their cell-free DNA (cf-DNA) testing facilities, efficiency, development, ex-factory prices, revenue and global market share for each of the covered companies. Regions Europe China Division South East Asia India Type Donor division by function Oncology Gynecology transplantation Segment by regions North America Europe China Segment by type Donor
Noncapsulated DNA that comes into the bloodstream during apoptosis and necrosis is non-encapsulated DNA. Throughout normal body activity, this cell-free DNA is cleared up by macrophages, but overproduction of cells throughout cancer produces extra cfDNA in the blood. CfDNA is present in blood, plasma, urine, or other body fluids and has a medical significance in the treatment, monitoring and identification of various noninvasive conditions.
Cell-free DNA testing markets grow fast due to growing cancers, increasing occurrence of chromosomal disorder infants, and growing demand for non-invasive test procedures. The market has also increased rapidly due to an increasing number of late pregnancies. Some of the factors hindering market growth are the higher research costs with less reimbursement facilities, lack of professional healthcare workers and absence of standardization. For gynecology, oncology and transplantation the cell free DNA testing finds its use. In the future, demand for these will increase as obesity, shifting lifestyles, and an unhealthy diet are rising.
Major Key Points in Table of Content:
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349